Bladder Cancer

In patients whose solid<strong> </strong>tumors harbor a mutation in <em>KRAS </em>G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research&ndash;National Cancer Institute&ndash;European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.

In an interview with&nbsp;Targeted Oncology, Pavlos Msaouel, MD, PhD, discussed the findings from the trial evaluating sitravatinib plus nivolumab in patients with advanced/metastatic urothelial carcinoma. He also highlighted the next steps for this combination regimen.

Building upon the initial successes of anti&ndash;PD-1 and anti&ndash;CTLA-4 therapies has been a major focus of drug development over the past several years&mdash;basically, in search of other agents that could generate &ldquo;immune-synergy.&rdquo; What the term means and implies is critically important: It refers to drugs that work better together than alone (or in sequence) through their individual mechanisms of action to enhance the host immune-response to cancer.

In an interview with&nbsp;Targeted Oncology, Scott T. Tagawa, MD, discussed the findings from the TROPHY-U-O1 trial presented at the 2019 ESMO Congress and shared his thoughts on the next steps for sacituzumab govitecan.

Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.